HSV Publications

Genital Herpes Infection: Progress and Problems (Jun 2023)

Estimated economic burden of genital herpes and HIV attributable to HSV type 2 infections in 90 low-and middle-income countries: A modeling study (Dec 2022)

Comparison of HSV-1 genetic diversity between adult sexual transmission partners with genital infection (May 2022)

Diagnosis and Management of Genital Herpes: Key Questions and Review of the Evidence for the 2021 CDC and Prevention Sexually Transmitted Infections Treatment Guidelines (Apr 2022)

Epidemiology, clinical presentation, and antibody response to primary infection with HSV type 1 and type 2 in young women (Feb 2013)

HSV type 2 serological testing and psychosocial harm: a systematic review (Dec 2011)

The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive women (Oct 2011)

Genital HSV-1 infections (Jun 2006)

Genital herpes in a primary care clinic: demographic and sexual correlates of HSV type 2 infection (Mar 1997)

Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of HSV-1 and HSV-2 Infection in a Clinical Setting (Dec 2017)

Serologic Testing for HSV-1 and HSV-2 Infection (Oct 2002)

Genital herpes: review of the epidemic and potential use of type-specific serology (Jan 1999)

Selective retention of virus-specific tissue-resident T cells in healed skin after recovery from herpes zoster (Nov 2022)

HLA-B*57:01 Complexed to a CD8 T-Cell Epitope from the HSV-2 ICP22 Protein Binds NK and T Cells through KIR3DL1 (May 2022)

HSV-2-specific human female reproductive tract tissue resident memory T cells recognize diverse HSV antigens (Mar 2022)

Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection (May 2013)

Rapid localized spread and immunologic containment define HSV-2 reactivation in the human genital tract (Apr 2013)

An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of HSV-2 infection (Oct 2012)

Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition (Aug 2009)

Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection (Nov 2022)

Genital Shedding of HSV Among Symptomatic and Asymptomatic Persons With HSV-2 Infection (Apr 2011)

Persistent genital HSV-2 shedding years following the first clinical episode (Jan 2011)

Frequent release of low amounts of HSV from neurons: results of a mathematical model (Nov 2009)

Rapidly cleared episodes of HSV reactivation in immunocompetent adults (Oct 2008)

Diagnosis and Management of Genital Herpes: Key questions and review of the evidence for the 2021 CDC STI Treatment Guidelines (Apr 2022)

Helicase-Primase Inhibitor Pritelivir for HSV-2 Infection (Jan 2014)

Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials (Feb 2012)

Valacyclovir and acyclovir for suppression of shedding of HSV in the genital tract (Oct 2004)

Suppression of subclinical shedding of HSV type 2 with acyclovir (Jan 1996)

HSV-2 transmission probability estimates based on quantity of viral shedding (Mar 2014)

Knowledge of partners’ genital herpes protects against HSV type 2 acquisition (Jul 2006)

Once-daily valacyclovir to reduce the risk of transmission of genital herpes (Jan 2004)

A prospective cohort study of partner testing for HSV and sexual behavior during pregnancy (Aug 2012)

Genital HSV detection among HIV-1-infected pregnant women in labor (Mar 2011)

Effect of serologic status and cesarean delivery on transmission rates of HSV from mother to infant (Jan 2003)

Current status and prospects for development of an HSV vaccine (Mar 2014)

Efficacy results of a trial of a herpes simplex vaccine (Jan 2012)

Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons (Nov 2011)

Population level impact of an imperfect prophylactic vaccine for HSV-2 (May 2010)

High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover (Jun 2013)

Rapidly cleared episodes of oral and anogenital HSV shedding in HIV-infected adults (Aug 2010)

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2 (Feb 2010)

Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa (May 2008)

Prior HSV Infection and the Risk of Herpes Zoster (Jul 2023)

Genital HSV Type 2 Suppression With Valacyclovir Is Not Associated With Changes in Nugent Score or Absolute Abundance of Key Vaginal Bacteria (Mar 2023)